Cargando…

CCL5 as a Prognostic Marker for Survival and an Indicator for Immune Checkpoint Therapies in Small Cell Lung Cancer

The standard treatment for small cell lung cancer (SCLC) has not changed in decades. Recently, important advances have been made in immunotherapy. However, analysis of these trials suggests that only a small proportion of patients benefit from immune checkpoint blockade (ICB). Identifying these pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tang, Yichun, Hu, Yueyang, Niu, Yuchun, Sun, Lei, Guo, Linlang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891515/ https://www.ncbi.nlm.nih.gov/pubmed/35252266 http://dx.doi.org/10.3389/fmed.2022.834725

Ejemplares similares

MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer
por: Sun, Lei, et al.
Publicado: (2021)

Prognosis of Lung Adenocarcinoma Patients With NTRK3 Mutations to Immune Checkpoint Inhibitors
por: Niu, Yuchun, et al.
Publicado: (2020)

The role of laboratory tests as a prognostic marker for immune-checkpoint therapy in non-small cell lung cancer
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2
por: Niu, Yuchun, et al.
Publicado: (2017)

Reduced FEV(1) as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors
por: Shen, Yi-Luen, et al.
Publicado: (2022)

Catenin Alpha-2 Mutation Changes the Immune Microenvironment in Lung Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitors
por: Wen, Yang, et al.
Publicado: (2021)

Predictive Markers for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
por: Ushio, Ryota, et al.
Publicado: (2022)

Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non–small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Yu, Xiaolin, et al.
Publicado: (2021)

CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer
por: Zhang, Man, et al.
Publicado: (2020)

Bioinformatic Analysis of Prognostic Value of SNTG2 with Immune Implications in Lung Adenocarcinoma
por: Zhou, Jian, et al.
Publicado: (2022)

Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)
por: Brueckl, Wolfgang M., et al.
Publicado: (2020)

Comprehensive Statistical Exploration of Prognostic (Bio-)Markers for Responses to Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer
por: Hiltbrunner, Stefanie, et al.
Publicado: (2021)

ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling
por: Zheng, Meng, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Associated Thrombotic Thrombocytopenic Purpura in a Patient With Metastatic Non-Small-Cell Lung Cancer
por: De Filippis, Samantha, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and the Heart
por: Mocan-Hognogi, Diana Larisa, et al.
Publicado: (2021)

Immune Checkpoint Gene Expression Profiling Identifies Programmed Cell Death Ligand-1 Centered Immunologic Subtypes of Oral and Squamous Cell Carcinoma With Favorable Survival
por: Yu, Yang, et al.
Publicado: (2022)

Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival
por: Ornelas, Mariana, et al.
Publicado: (2023)

The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity
por: Moss, Emily M., et al.
Publicado: (2022)

Immune checkpoint inhibitor induced nephrotoxicity: An ongoing challenge
por: Catalano, Martina, et al.
Publicado: (2022)

High levels of CCL2 or CCL4 in the tumor microenvironment predict unfavorable survival in lung adenocarcinoma
por: Li, Lei, et al.
Publicado: (2018)

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors
por: Meyers, Daniel E., et al.
Publicado: (2019)

Identification of prognostic nutritional index as a reliable prognostic indicator for advanced lung cancer patients receiving immune checkpoint inhibitors
por: Yan, Xuebing, et al.
Publicado: (2023)

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab
por: Yamaguchi, Ou, et al.
Publicado: (2019)

Checkpoint molecules on infiltrating immune cells in colorectal tumor microenvironment
por: Talaat, Iman M., et al.
Publicado: (2022)

Indicators of responsiveness to immune checkpoint inhibitors
por: Shields, Bradley D., et al.
Publicado: (2017)

Prognostic Role and Diagnostic Power of Seven Indicators in COVID-19 Patients
por: Ding, Lili, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
por: Chen, Xue, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Lung Cancer: Role of Biomarkers and Combination Therapies
por: Maung, Tun Zan, et al.
Publicado: (2020)

Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
por: Wang, Wenxian, et al.
Publicado: (2020)

Clinical Indicators for Long-Term Survival with Immune Checkpoint Therapy in Advanced Hepatocellular Carcinoma
por: Monge, Cecilia, et al.
Publicado: (2021)

Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy
por: Tu, Megan M., et al.
Publicado: (2020)

Survival and biomarkers for cachexia in non‐small cell lung cancer receiving immune checkpoint inhibitors
por: Murata, Daiki, et al.
Publicado: (2023)

A new immune signature for survival prediction and immune checkpoint molecules in non-small cell lung cancer
por: Han, Shuai, et al.
Publicado: (2023)

Survival prediction and response to immune checkpoint inhibitors: A prognostic immune signature for hepatocellular carcinoma
por: Xu, Ying, et al.
Publicado: (2020)

Integrating Tumor Stroma Biomarkers With Clinical Indicators for Colon Cancer Survival Stratification
por: Chen, Yong, et al.
Publicado: (2020)

Identification CCL2,CXCR2,S100A9 of the immune-related gene markers and immune infiltration characteristics of inflammatory bowel disease and heart failure via bioinformatics analysis and machine learning
por: Luo, Xu, et al.
Publicado: (2023)

Increased CDCA2 Level Was Related to Poor Prognosis in Hepatocellular Carcinoma and Associated With Up-Regulation of Immune Checkpoints
por: Tang, Mengying, et al.
Publicado: (2022)

Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events
por: Nakamura, Yoshiyuki
Publicado: (2019)

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders
por: Coureau, Michelle, et al.
Publicado: (2020)

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
por: Shen, Pan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jbi7h1d9hbugna4a19483vqn5g